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Abstract:  Objective: To incorporate patients' views in the design of a measure of satisfaction with treatment 
for diabetic retinopathy, to be used in evaluation of currently available and anticipated new therapies. This 
report focuses on development of the Retinopathy Treatment Satisfaction Questionnaire (RetTSQ). 
Development of the RetDQoL quality of life measure in the same interviews is reported elsewhere. 
Methodology: During semi-structured interviews with 44 people with diabetic retinopathy (11 in each of 2 UK 
and 2 German hospitals), interviewees described their experiences of retinopathy treatments and reactions 
to possible new therapies. They completed and commented on a draft RetTSQ, based on the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ). Drafts were revised and translated between centres, 
incorporating patients' views. Interviews were audio-taped, transcribed and content analysed. Results: 
Interviewees were 26 men, 18 women; median age 60.8 (range: 28-82), having background or proliferative 
retinopathy with a range of severity (one or both eyes); median visual acuity better eye 0.80 (range: 0.0025 
(hand motion only) - 1.20 (6/5 vision)). Satisfaction dimensions included treatment effectiveness, emotional 
and physical experiences before, during and after treatment, information provision and influence over 
treatment. The resulting RetTSQ has 13 items and an open question, allowing additional items to be 
developed if needed for future treatments. Conclusions: The RetTSQ has face and content validity for a wide 
range of people with diabetic retinopathy in two European countries. It is ready for further validation and for 
use in research and clinical contexts.  
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Abstract.  
Objective: To incorporate patients’ views in the design of a measure of satisfaction with treatment 
for diabetic retinopathy, to be used in evaluation of currently available and anticipated new 
therapies. This report focuses on development of the Retinopathy Treatment Satisfaction 
Questionnaire (RetTSQ). Development of the RetDQoL quality of life measure in the same 
interviews is reported elsewhere. Methodology: During semi-structured interviews with 44 people 
with diabetic retinopathy (11 in each of 2 UK and 2 German hospitals), interviewees described 
their experiences of retinopathy treatments and reactions to possible new therapies. They 
completed and commented on a draft RetTSQ, based on the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ). Drafts were revised and translated between centres, incorporating patients’ 
views. Interviews were audio-taped, transcribed and content analysed. Results: Interviewees were 
26 men, 18 women; median age 60.8 (range: 28-82), having background or proliferative 
retinopathy with a range of severity (one or both eyes); median visual acuity better eye 0.80 
(range: 0.0025 (hand motion only) – 1.20 (6/5 vision)). Satisfaction dimensions included treatment 
effectiveness, emotional and physical experiences before, during and after treatment, information 
provision and influence over treatment. The resulting RetTSQ has 13 items and an open question, 
allowing additional items to be developed if needed for future treatments. Conclusions: The 
RetTSQ has face and content validity for a wide range of people with diabetic retinopathy in two 
European countries. It is ready for further validation and for use in research and clinical contexts.  
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1. Introduction 
 
Diabetic retinopathy (DR) is the leading cause of blindness amongst 16-64 year-olds[1]. 
Current management is limited to screening, laser photocoagulation and vitrectomy[2], 
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with increased efforts to improve glycaemic control. Benefits of laser photocoagulation 
[e.g.3] are generally considered to outweigh its disadvantages[e.g.4]. DR and its 
management can have negative impacts, even before vision loss. To measure these, the 
individualized Retinopathy Dependent Quality of Life measure (RetDQoL)[5] was 
developed, modelled on the Audit of Diabetes Dependent Quality of Life[6]. The 
Retinopathy Treatment Satisfaction Questionnaire (RetTSQ), developed in parallel with 
the RetDQoL, is the focus of the present report. The RetTSQ needs to be relevant to 
current and future therapies, so is modelled on the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ)[7]), which suits a wide range of treatment types. The DTSQ 
previously formed the basis of measures for end-stage renal disease (RTSQ)[8], Human 
Immunodeficiency Virus (HIVTSQ)[9] and genital herpes (GHerpTSQ)[10]. The 
RetTSQ needs to cover issues important and relevant to the range of people with DR, be 
easily understood and completed and include issues appropriate internationally, so it can 
be used in multinational trials. Medtap, Maryland, USA conducted four focus groups 
(unpublished) asking people with DR about laser treatments. Content analysis of the 
transcripts by the present authors suggested some issues to be covered by RetTSQ items. 
By designing the RetTSQ in four phases, alternating between UK and Germany, any 
translation problems could be resolved, to minimise difficulties with further translations. 
 
2. Materials and Methods 
 
In each of four hospital centres in turn, patients described experiences of DR 
treatments in a semi-structured interview and completed a draft RetTSQ. Qualitative and 
quantitative data were collected during questionnaire completion, but because item 
wording changed throughout the study, scores were not combined for statistical analysis. 
Local Research Ethics Committees gave approval. Demographic and clinical details 
were collected. Four psychologists interviewed in pairs: 3 were English, one with fluent 
German; the fourth was German, fluent in English. Centres 1 and 3 were diabetes centres 
in Scotland and Southern England; Centres 2 and 4 were eye clinics in Southwest and 
Northwest Germany. To sample as wide a range of views as possible, each centre 
selected 2 patients with non-proliferative and 9 with proliferative DR, all >18 years old, 
varying in age, gender, education, working background and experience of DR 
treatments. The hour-long interviews were audio-taped and transcribed. Each followed a 
question route, comprising open questions to encourage people to talk freely about views 
and experiences of treatments, and closed questions to obtain specific details. 
Interviewer and assistant completed a checklist and took notes. RetTSQ Draft 1 was in 
English. During design of the Macular Disease Dependent Quality of Life measure 
(MacDQoL)[11], people with macular disease preferred a vertical layout, so RetTSQ 
response options (6-0) were listed vertically, in Arial 16 point bold typeface.  
Each interviewee could suggest new items or amendments to existing items. If an 
interviewee could not complete the RetTSQ unaided, the interviewer read it aloud and 
recorded responses. For 11 patients in each of Centres 1 and 2 and for 8 in Centres 3 and 
4, semi-structured questioning was first, then RetTSQ completion and discussion. This 
allowed spontaneous mention of sources of satisfaction /dissatisfaction, uninfluenced by 
the questionnaire. In Centres 3 and 4, three patients completed the RetTSQ first, 
‘thinking aloud’ to convey their interpretation of items. No spontaneous mentions were 
possible. Their comments were used to confirm that items were understood as intended, 
without prior discussion. Data from notes and checklists were content analysed, 
summarised and checked against tape transcripts. The number of spontaneous mentions 
relating to each item, reasons for missing any item, and distribution of scores were 
recorded. The researchers discussed a document summarising each centre’s results, 
before and during preparation and translation of the draft for the next centre. The 
RetTSQ was finalized in English and German after Centre 4. 
 
3. Results 
 
Mean age was 57.1 years (sd 14.5); 26 men, 18 women. Diabetes was treated by diet 
(n=1), tablets (n=14), insulin (n=29); mean diabetes duration 19.4 years (sd 12.2); mean 
recent HbA1c 8.0% (sd 1.5). Clinical data were available for 43 interviewees: mean time 
since DR diagnosis 5.6 years (sd 4.8); mean corrected distance visual acuity (DVI) better  
 
Table 1  
Final RetTSQ items (following interviews), showing number of spontaneous mentions by 38 respondents 
The following questions are about your experience of treatment for your diabetic eye problems – the eye 
problems often caused by diabetes. Your eye treatment includes: medications (e.g. tablets, eye drops); visits to 
the doctor and hospital for check-ups and laser treatment or surgery. In this questionnaire, please: think about 
the treatment for your diabetic eye problems, not for your diabetes itself; think about your eye treatment over 
the past 12 months. Answer each question by putting an "X" in the box next to one of the numbers from 6 to 0. 
no Short title n/38 Source Wording Response range 
1  
 
satisfaction 1 DTSQ How satisfied are you with the treatment for your 
diabetic eye problems? 
very satisfied/ 
dissatisfied 
2 
 
how well 
working 
20 interviews 
DTSQ  
How well do you feel the treatment for your 
diabetic eye problems is working? 
very well/ badly 
3 
 
side/ 
after 
effects 
19 HIVTSQ  How bothered are you by any side effects or after 
effects of the treatment for your diabetic eye 
problems? 
not at all /very 
bothered  
 
4 
 
discomfort/ 
pain 
22 RTSQ How bothered are you by any discomfort or pain 
from the treatment for your diabetic eye problems? 
not at all/very 
bothered 
 
5 
 
not 
unpleasant 
11 USA focus 
groups 
How unpleasant do you find the treatment for your 
diabetic eye problems? 
not at all/very 
unpleasant 
6 
 
difficulty  9 interviews How difficult for you is the treatment for your 
diabetic eye problems? 
very easy/ 
difficult 
7 
 
apprehen-
sion 
12 interviews How apprehensive do you feel about the treatment 
for your diabetic eye problems? 
not at all/ very 
apprehensive 
8 influence 7 interviews How satisfied are you with the influence you have 
over the treatment for your diabetic eye problems? 
very satisfied/ 
dissatisfied 
9 Safety 7 interviews How satisfied are you with the safety of the 
treatment for your diabetic eye problems? 
very satisfied/ 
dissatisfied 
10 time-
consuming 
5 USA focus 
groups 
How time-consuming do you find the treatment for 
your diabetic eye problems? 
not at all/very 
time-consuming 
11 informatio
n 
8 interviews How satisfied are you with the information 
provided about the treatment for your diabetic eye 
problems? 
very satisfied/ 
dissatisfied 
12 encourage  1 interviews 
DTSQ 
recommen
d 
Would you encourage someone else with diabetic 
eye problems like yours to have your kind of 
treatment? 
yes, I would/ no, 
I would 
definitely not 
encourage them 
13 continue/ 
repeat 
1 DTSQ 
continue  
How satisfied would you be to continue or repeat 
the treatment for your diabetic eye problems? 
very satisfied/ 
dissatisfied 
eye 0.76 (sd 0.29). The most visually impaired could detect only hand motion at 1 metre 
with the better eye, coded 0.0025[12]; the least impaired had DVI 6/5 (1.20) in both 
eyes; 36 had received photocoagulation (laser or xenon), of whom ten had received one 
or more vitrectomy; 7 had experienced neither. As well as DR, 4 had an unoperated 
cataract in one eye and 4 in both eyes; 4 had glaucoma in one eye and 4 in both eyes; one 
had macular disease in both eyes; 7 had ‘another’ eye condition (2 in one eye; 5 in both). 
 Forty completed the RetTSQ: five of these needed interviewer assistance (3 due to 
poor vision and 2 because their pupils had been dilated). Four contributed views for 
qualitative analysis but did not complete the RetTSQ due to time constraints. The final 
RetTSQ has 13 items. Item 14 requests any further sources of satisfaction/dissatisfaction. 
Table 1 shows how many of the 38 interviewees mentioned each item content 
spontaneously. Requests for clarification or missing an item indicated its 
inappropriateness to patient experiences of DR treatment, so it was modified or dropped. 
Some modified items originating from questionnaires for other conditions[7-10] were 
retained; 7 final items arose solely from interviews. Twenty people did not recognise the 
term retinopathy/diabetic retinopathy as describing their condition so the term diabetic 
eye problems is used in the final RetTSQ. Illustrative quotes for each item (Table 2) are 
evidence of face and content validity. Each item provided scores across the scale.  
 
Table 2  
Patient quotes to illustrate each of the 13 final RetTSQ items 
no short title of item Quotes (G=German; B=British; M=man; W=woman ; age in years) 
1  satisfaction After the operation, I’m incredibly satisfied. (GM67) 
2 
 
how well working If it worked! If someone came along and said ‘Would you like to try a new treatment?’ 
and it might or might not work, my immediate reaction would be to try it. Provided it’s got a reasonable 
chance of success. (BM68) 
3 
 
side/after effects Great light sensitivity…. principally after the laser treatment. (GM47). Another tablet! 
Well we think that’s what’s given me this terrible indigestion. (BW68) 
4 discomfort/pain My eyes are a bit sore after. (BM68) God, the thing was totally painful! (GM43) 
5 
 
(not)unpleasant Because you’re tense and you’re sitting there and it’s not very pleasant, I think it 
probably seems longer than it is. (BW52) 
6 
 
difficulty At first, I found it very disorientating because you had bright light flooding the eye which is 
very, very difficult to keep the eye still. (BM46) 
7 
 
apprehension The first time, I was ‘Oh, what’s going to happen to me?… I was a wee bit apprehensive 
about what was going to happen. (BM68) 
8 influence I think it is good, provided you can trust the person who is doing it. You really are very 
dependent on their skills and you’re dependent on yourself not moving. (BW74) 
9 safety But then there’s a big risk when they’re working with the eye… I say it’s maybe that I’ve done 
something wrong that he stops. If he hits the wrong place, it would really destroy it. (BW74) 
10 time-consuming But yesterday I had over an hour’s wait. The first part of the process was no problem, but 
.. I had to sit around waiting for the laser treatment. (BM68) 
11 information I said ‘I don’t mind what they do so long as you let me know’.(BW68). After the first couple 
of treatments, I had expected it to get better but it hasn’t. If anything, it’s got slightly worse. (BW48) 
12 encourage I mean the recommendation is going to come from medical staff… I can encourage you to do 
it, but I’m in no position to recommend you to have it. (BM65) 
13 continue/ repeat After the first treatment, I said I’d rather go blind than have any more. (BM56) 
 
4. Discussion 
 
The RetTSQ, based directly on patient experiences and views, is the first measure of 
satisfaction with treatment for DR. Suitable for a wide range of treatment types, it 
focuses on treatment satisfaction, rather than quality of life, which may be measured 
with the RetDQoL[5]. People recalling photocoagulation received many years previously 
reported some particularly unpleasant experiences. Recent experiences of laser 
photocoagulation were profoundly negative for some, whilst others found it relatively 
straightforward, painless and unthreatening. Interviewees highlighted the role of doctors 
in reducing or preventing anxiety and providing realistic expectations of treatments. 
Some patients expected their vision to benefit from ‘laser treatment’, so were 
disappointed to find no change or even deterioration. Whilst focal treatment for macular 
edema can increase the chances of visual improvement, pan-retinal photocoagulation can 
adversely affect vision[4]. Adequate explanation of DR and its treatment can help 
patients to understand why ‘laser treatment’ is painful on some occasions but not others. 
It may make existing treatments more acceptable, improve adherence to treatment 
recommendations and aid acceptance of new therapies.  
The RetTSQ is ready for use and psychometric validation, which will indicate optimal 
item selection and scoring procedure (scales and/or subscales). To use the RetTSQ, 
please contact copyright holder, Prof Clare Bradley: email c.bradley@rhul.ac.uk. 
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